<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353912</url>
  </required_header>
  <id_info>
    <org_study_id>CVAA489A2402</org_study_id>
    <nct_id>NCT00353912</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension</brief_title>
  <official_title>A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the blood pressure lowering effects of a&#xD;
      valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of&#xD;
      Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in MSSBP at week 8</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline MSSBP after 2, 4 and 12 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline MSDBP after 2, 4, 8 and 12 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients reaching overall BP control (MSSBP &lt; 140 mmHg and MSDBP &lt; 90mmHg) after 12 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of safety and tolerability after 12 weeks of treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">571</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan + amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Moderate to severe high blood pressure. This is defined as a systolic pressure (the&#xD;
             top number) greater than or equal to 160 mmHg and less than 200 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or hypersensitivity to ARBs, CCBs, thiazide diuretics&#xD;
&#xD;
          -  Inability to stop all prior blood pressure medications safely&#xD;
&#xD;
          -  Systolic BP ≥ 200 mmHg and/or diastolic BP ≥ 120 mmHg&#xD;
&#xD;
          -  Controlled blood pressure (systolic BP &lt; 140 mmHg) taking more than 3 antihypertensive&#xD;
             medications at screening&#xD;
&#xD;
          -  Systolic BP ≥ 140 mmHg and &lt; 180 mmHg taking more than two antihypertensive&#xD;
             medications at screening&#xD;
&#xD;
          -  Systolic BP ≥ 180 mmHg taking more than one antihypertensive medication at screening&#xD;
&#xD;
          -  History of autoimmune diseases&#xD;
&#xD;
          -  History of multiple drug allergies&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Pancreatic injury within 1 year of screening&#xD;
&#xD;
          -  Evidence of kidney impairment or history of dialysis&#xD;
&#xD;
          -  Any surgical or medical condition which might alter the absorption, distribution,&#xD;
             metabolism, or excretion of any drug. This could include currently active gastritis,&#xD;
             ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, would be excluded UNLESS they are post-menopausal, surgically&#xD;
             sterile OR are using acceptable methods of contraception. The use of hormonal&#xD;
             contraceptives is not allowed&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  History of malignancy of any organ system within the past five years&#xD;
&#xD;
          -  Any severe, life-threatening disease within the past five years&#xD;
&#xD;
          -  History of drug or alcohol abuse within the last 2 years.&#xD;
&#xD;
          -  History of stroke, angioplasty, coronary artery bypass graft surgery, heart attack or&#xD;
             unstable angina&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Poorly controlled Type 2 diabetes&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  Arrhythmia&#xD;
&#xD;
          -  Significant valvular heart disease&#xD;
&#xD;
          -  Active gout&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>E. Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul;23(7):479-89. doi: 10.1038/jhh.2008.153. Epub 2009 Jan 29.</citation>
    <PMID>19190658</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 17, 2006</study_first_submitted>
  <study_first_submitted_qc>July 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2006</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood</keyword>
  <keyword>Venous</keyword>
  <keyword>Systolic</keyword>
  <keyword>Diastolic</keyword>
  <keyword>Pulse</keyword>
  <keyword>Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

